Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2041 to 2055 of 8929 results

  1. Anitocabtagene autoleucel for treating relapsed or refractory multiple myeloma [ID6549]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  2. Tirzepatide for treating type 2 diabetes [ID3938]: review proposal consultation

    We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.

    Technology appraisal guidance
    In consultation

  3. Neonatal infection: antibiotics for prevention and treatment - update: draft guidance consultation

    We are listening to your views on this NICE guideline. Comments close 4 March 2026.

    NICE guideline
    In consultation

  4. Heart failure - sacubitril valsartan [ID822]: review proposal consultation

    We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.

    Technology appraisal guidance
    In consultation

  5. Empagliflozin for treating chronic heart failure with reduced ejection fraction [ID3826]: review proposal consultation

    We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.

    Technology appraisal guidance
    In consultation

  6. Empagliflozin in combination therapy for treating type 2 diabetes: review proposal consultation

    We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.

    Technology appraisal guidance
    In consultation

  7. Ertugliflozin in a triple therapy regimen for treating type 2 diabetes [ID1160]: review proposal consultation

    We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.

    Technology appraisal guidance
    In consultation

  8. Ertugliflozin as monotherapy and in dual therapy for treating type 2 diabetes [ID1158]: review proposal consultation

    We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.

    Technology appraisal guidance
    In consultation

  9. Dapagliflozin in triple therapy regimens for treating type 2 diabetes [ID962]: review proposal consultation

    We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.

    Technology appraisal guidance
    In consultation

  10. Diabetes (type 2) - canagliflozin, dapagliflozin and empagliflozin (monotherapy) [ID756]: review proposal consultation

    We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.

    Technology appraisal guidance
    In consultation

  11. Dapagliflozin for treating heart failure with reduced ejection fraction [ID1656]: review proposal consultation

    We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.

    Technology appraisal guidance
    In consultation

  12. Canagliflozin in combination therapy for treating type 2 diabetes: review proposal consultation

    We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.

    Technology appraisal guidance
    In consultation

  13. Dapagliflozin in combination therapy for treating type 2 diabetes: review proposal consultation

    We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.

    Technology appraisal guidance
    In consultation

  14. Lurbinectedin with atezolizumab for maintenance treatment of extensive-stage small-cell lung cancer [ID6526]

    In development Reference number: GID-TA11502 Expected publication date:  02 December 2026

    Technology appraisal guidance
    In development

  15. Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6442]

    In development Reference number: GID-TA11424 Expected publication date:  07 May 2026

    Technology appraisal guidance
    In development